Towards 2022: What are prevention and risk reduction in Alzheimer’s disease?

Hacia 2022: ¿Qué son la prevención y la reducción de riesgos en la enfermedad de Alzheimer?

dc.creatorAllegri, Ricardo Francisco
dc.creatorRomán, Fabián
dc.creatorBarceló, Ernesto
dc.date2023-05-17T23:30:36Z
dc.date2023-05-17T23:30:36Z
dc.date2021-09-10
dc.date.accessioned2023-10-03T19:40:49Z
dc.date.available2023-10-03T19:40:49Z
dc.identifierAllegri, R. F., Román, F. ., & Barceló, E. (2021). Towards 2022: What are prevention and risk reduction in Alzheimer’s disease? Hacia 2022: ¿Qué son la prevención y la reducción de riesgos en la enfermedad de Alzheimer?. Journal of Applied Cognitive Neuroscience, 2(2), e00004009. https://doi.org/10.17981/JACN.2.2.2021.00
dc.identifierhttps://hdl.handle.net/11323/10143
dc.identifier10.17981/JACN.2.2.2021.00
dc.identifier2745-0031
dc.identifierCorporación Universidad de la Costa
dc.identifierREDICUC - Repositorio CUC
dc.identifierhttps://repositorio.cuc.edu.co/
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/9171360
dc.descriptionThe increase in life expectancy has led in recent years to neurodegenerative pathologies, such as Alzheimer’s disease, that were strange in the last century, now become so frequent that there is talk of a new epidemic. It is estimated that approximately 50 000 000 patients suffer dementia around the world (World Health Organization-WHO, 2012). Alzheimer’s disease is the most common dementia, and brain pathology begin up to 25 years before the first clinical symptoms appear (Bateman et al., 2012). Thus, Alzheimer currently has five stages, the pre-symptomatic, the mild cognitive impairment, and the mild, moderate and severe dementia.Since the original description in 1904 by Alois Alzheimer, the disease could only be definitively diagnosed by neuropathological, and the clinical diagnosis was only probable or possible (NINCDS ADRDA, McKhan et al., 1984). In recent years, more de-tailed knowledge of structural neuroimaging (hippocampal volume by MRI), metabolic (FDG-PET), molecular (amyloid PET), and cerebrospinal fluid studies (Aβ42, tau and f-tau) make it possible to diagnose Dementia due to Alzheimer’s disease while the patient is alive (McKhan et al., 2011) and even at pre-symptomatic stage of the disease (Sperling et al, 2011).
dc.format8 páginas
dc.formatapplication/pdf
dc.formatapplication/pdf
dc.languageeng
dc.publisherCorporación Universidad de la Costa
dc.publisherColombia
dc.relationJournal of Applied Cognitive Neuroscience
dc.relationBateman, R. J.; Xiong, C.; Benzinger, T.; Fagan, A. M.; Goate, A.; Fox, N. C.; Marcus, D. S.; Cairns, N. J.; Xie, X., Blazey, T. M.; Holtzman, D. M.; Santacruz, A.; Buckles, V.; Oliver, A.; Moulder, K.; Aisen, P. S.; Ghetti, B.; Klunk, W. E.; McDade, E.; Martins, R. N.; Masters, C. L.; Mayeux, R.; Ringman, J. M.; Rossor, M. N.; Schofield, P. R.; Sperling, R. A.; Salloway, S. & Morris, J. C. (2012). Clinical and Biomarker Changes in Dominantly Inherited Alzheimer’s disease. The New England Journal of Medicine, 367(9), 795–804. https://doi.org/10.1056/NEJMoa1202753
dc.relationBrookmeyer, R.; Johnson, E.; Ziegler-Graham, K. & Arrighi, H. M. (2007). Forecasting the global burden of Alzheimer’s disease. Alzheimer’s & Dementia, 3(3), 186–191. https://doi.org/10.1016/j.jalz.2007.04.381
dc.relationCummings, J.; Lee, G.; Zhong, K.; Fonseca, J. & Taghva, K. (2021). Alzheimer’s disease drug development pipeline: 2021. Alzheimer’s Dement, 7(1), 1–24. https://doi.org/10.1002/trc2.12179
dc.relationFeinleib, M. (2001). A Dictionary of Epidemiology, Fourth Edition - Edited by John M. Last, Robert A. Spasoff, and Susan S. Harris. American Journal of Epidemiology, 154(1), 93–94. https://doi.org/10.1093/aje/154.1.93-a
dc.relationGetsios, D.; Blume, S.; Ishak, K. J.; Maclaine, G. & Hernández, L. (2012). An economic evaluation of early assessment for Alzheimer’s disease in the United Kigdom. Alzheimer & Dementia, 8(1), 22–30. https://doi.org/10.1016/j.jalz.2010.07.001
dc.relationHodes, J. F.; Oakley, C. L.; O’Keefe, J. H.; Lu, P.; Galvin, J. E.; Saif, N.; Bellara, S.; Rahman, A.; Kaufman, Y.; Hristov, H.; Rajji, T. K.; Fosnacht, A. M.; Patel, S.; Merrill, D. A.; Kaiser, S.; Meléndez-Cabrero, J.; Melendez, J. A.; Krikorian, R. & Isaacson, R. S. (2019). Alzheimer’s “Prevention ”vs.“ Risk Reduction: Transcending Semantics for Clinical Practice. Frontiers in Neurology, 9(1), 1–8. https://doi.org/10.3389/fneur.2018.01179
dc.relationKivipelto, M.; Mangialasche, F.; Snyder, H. M.; Allegri, R. F.; Andrieu, S.; Arai, H.; Baker, L.; Belleville, S.; Brodaty, H.; Brucki, S. M.; Calandri, I.; Caramelli, P.; Chen, C.; Chertkow, H.; Chew, E.; Choi, S. H.; Chowdhary, N.; Crivelli, L.; De La Torre, R.; Du, Y.;Dua, T.; Espeland, M.; Feldman, H. H.; Hartmanis, M.; Hartmann, T.; Heffernan, M.; Henry, C. J.; Hong, C. H.; Håkansson, K.; Iwatsubo, T.; Jeong, J. H.; Jimenez-Maggiora, G.; Koo, E. H.; Launer, L. J.; Lehtisalo, J.; Lopera, F.; Martínez-Lage, P.; Martins, R.; Middleton, L.; Molinuevo, J. L.; Montero-Odasso, M.; Moon, S. Y.; Morales-Pérez, K.; Nitrini, R.; Nygaard, H. B.; Park, Y. K.; Peltonen, M.; Qiu, C.; Quiroz, Y. T.; Raman, R.; Rao, N.; Ravindranath, V.; Rosenberg, A.; Sakurai, T.; Salinas, R. M.; Scheltens, P.; Sevlever, G.; Soininen, H.; Sosa, A. L.; Suemoto, C. K.; Tainta-Cuezva, M.; Velilla, L.; Wang, Y.; Whitmer, R.; Xu, X.; Bain, L. J.; Solomon, A.; Ngandu, T. & Carrillo, M. C. (2020). World-Wide FINGERS Network: A Global Approach to Risk Reduction and Prevention of Dementia. Alzheimers & Dement, 16(1), 1078–1094. https://doi.org/10.1002/alz.12123
dc.relationMcKhann, G.; Drachman, D.; Folstein, M.; Katzman, R.; Price, D. & Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology, 34(7), 939–944. https://doi.org/10.1212/wnl.34.7.939
dc.relationMcKhann, G. M.; Knopman, D. S.; Chertkow, H.; Hyman, B. T.; Jack, C. R. Jr, Kawas, C. H, Klunk, W. E; Koroshetz, W. J.; Manly, J. J.; Mayeux, R.; Mohs, R. C.; Morris, J. C.; Rossor, M. N.; Scheltens, P.; Carrillo, M. C.; Thies, B.; Weintraub, S. & Phelps, C. H. (2011). The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging– Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement, 7(3), 263–269. https://doi.org/10.1016/j.jalz.2011.03.005
dc.relationPrince, M.; Bryce, R. & Ferri, C. (2011). World Alzheimer Report 2011. The benefits of early diagnosis and intervention. London: ADI. Available: https://www.alzint.org/resource/world-alzheimer-report-2011/
dc.relationSperling, R. A.; Aisen, P. S.; Beckett, L. A.; Bennett, D. A.; Craft, S.; Fagan, A. M.; Iwatsubo, T.; Jack Jr, C. R.; Kaye, J.; Montine, T. J.; Park, D. C.; Reiman, E. M.; Rowe, C. C.; Siemers, E.; Stern, Y.; Yaffe, K.; Carrillo, M. C.; Thies, B.; Morrison-Bogorad, M.; Wagster, M. V. & Phelps, C. H. (2011). Towards defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement, 7, 280–292. https://doi.org/10.1016/j.jalz.2011.03.003
dc.relationWHO EMRO. (feb. 1, 2015). Health Promotion and Disease Prevention Through Population-Based Interventions, Including Action to Address Social Determinants and Health Inequity. Genebra: Regional Director/WHO. Available: http://www.emro.who.int/about-who/public-health-functions/health-promotion-disease-prevention.html
dc.relationWHO. (2012). Dementia: A Public Health Priority. London: WHO/ADI. Available: https://apps.who.int/iris/handle/10665/75263
dc.relationWimo, A. & Prince, M. (2010). World Alzheimer Report 2010. London: ADI. Available from https://www.alz.org/documents/national/world_alzheimer_report_2010.pdf
dc.relation8
dc.relation1
dc.relation2
dc.relation2
dc.rightsCopyright (c) 2021 Ricardo F. Allegri
dc.rightsAtribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightshttp://purl.org/coar/access_right/c_abf2
dc.sourcehttps://revistascientificas.cuc.edu.co/JACN/article/view/4009
dc.subjectAlzheimer’s
dc.subjectPrevention
dc.subjectReduction
dc.titleTowards 2022: What are prevention and risk reduction in Alzheimer’s disease?
dc.titleHacia 2022: ¿Qué son la prevención y la reducción de riesgos en la enfermedad de Alzheimer?
dc.typeArtículo de revista
dc.typehttp://purl.org/coar/resource_type/c_6501
dc.typehttp://purl.org/coar/resource_type/c_2df8fbb1
dc.typeText
dc.typeinfo:eu-repo/semantics/article
dc.typehttp://purl.org/redcol/resource_type/ART
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typehttp://purl.org/coar/version/c_970fb48d4fbd8a85
dc.coverage2022


Este ítem pertenece a la siguiente institución